Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $134,597.07 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 2,493 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $53.99, for a total transaction of $134,597.07. Following the completion of the transaction, the chief operating officer now owns 198,047 shares in the company, valued at approximately $10,692,557.53. This trade represents a 1.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Akero Therapeutics Price Performance

Akero Therapeutics stock traded up $1.55 during trading hours on Friday, reaching $55.11. 1,356,860 shares of the stock were exchanged, compared to its average volume of 1,476,598. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a market cap of $4.39 billion, a P/E ratio of -14.70 and a beta of -0.16. The stock has a 50 day moving average of $43.53 and a two-hundred day moving average of $40.13.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. Equities analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Citigroup lowered their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Bank of America lifted their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics presently has an average rating of "Buy" and an average target price of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

A number of large investors have recently modified their holdings of AKRO. RTW Investments LP raised its holdings in shares of Akero Therapeutics by 15.9% during the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after buying an additional 940,388 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Akero Therapeutics by 11.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,817,091 shares of the company's stock valued at $194,997,000 after acquiring an additional 495,119 shares during the last quarter. Vanguard Group Inc. raised its stake in Akero Therapeutics by 14.2% during the first quarter. Vanguard Group Inc. now owns 4,230,644 shares of the company's stock worth $171,256,000 after acquiring an additional 526,233 shares in the last quarter. Deep Track Capital LP lifted its holdings in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after acquiring an additional 800,216 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Akero Therapeutics by 93.3% in the 1st quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after purchasing an additional 557,794 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.